Teva launches cyclosporine ophthalmic emulsion in Canada

Teva Canada Ltd. announced the launch of Teva-Cyclosporine ophthalmic emulsion, 0.05%, a twice-daily eye drop used in the treatment of dry eye.

The subsidiary of Teva Pharmaceutical Industries Ltd. stated in a press release that cyclosporine ophthalmic emulsion is indicated for treating moderate to moderately severe aqueous-deficient dry eye disease characterized by moderate to moderately severe ocular staining, reduction in tear production and fluctuating visual symptoms, such as blurred vision.

Teva said that the drop is approved by Health Canada and is available immediately to pharmacies across Canada.

“The launch of Teva-Cyclosporine demonstrates Teva Canada's research and development capabilities and desire to continue to support niche patient groups, utilizing specialized technology,” the company said in the release.

Teva Canada Ltd. announced the launch of Teva-Cyclosporine ophthalmic emulsion, 0.05%, a twice-daily eye drop used in the treatment of dry eye.

The subsidiary of Teva Pharmaceutical Industries Ltd. stated in a press release that cyclosporine ophthalmic emulsion is indicated for treating moderate to moderately severe aqueous-deficient dry eye disease characterized by moderate to moderately severe ocular staining, reduction in tear production and fluctuating visual symptoms, such as blurred vision.

Teva said that the drop is approved by Health Canada and is available immediately to pharmacies across Canada.

“The launch of Teva-Cyclosporine demonstrates Teva Canada's research and development capabilities and desire to continue to support niche patient groups, utilizing specialized technology,” the company said in the release.